MAPT and Alzheimer disease: We and others have previously shown that blocking the apoE/Aβ interaction by Aβ12-28 P peptides could constitute a novel treatment for AD by reducing brain parenchymal and vascular amyloid burden as well as tau related pathology in several AD transgenic mice lines16–20.